Reports Q4 revenue $32.61M, consensus $32.6M. “Based on our fourth quarter results, we believe that the commercial initiatives implemented in the second half of 2025 are showing early signs of progress,” said Ron Kurtz, president and CEO of RxSight (RXST). “While there is still more work ahead, full year LAL growth reflected strong adoption as physicians and patients recognize the value of the company’s differentiated therapy. Our team remains committed to driving the disciplined execution that supports doctors as they deliver the benefits of high-quality customized vision to their patients.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RXST Upcoming Earnings Report: What to Expect?
- Spotify upgraded, Pinterest downgraded: Wall Street’s top analyst calls
- RxSight: Unique Adjustable IOL Technology Offset by Slowing Momentum and Execution Risks Supports Hold Rating
- RxSight initiated with a Market Perform at William Blair
- RxSight price target raised to $11 from $10 at Piper Sandler